| Literature DB >> 21222035 |
A C Weustink1, L A Neefjes, A Rossi, W B Meijboom, K Nieman, E Capuano, E Boersma, N R Mollet, G P Krestin, P J de Feyter.
Abstract
To conduct a comparison of the diagnostic performance of exercise bicycle testing and single-photon emission computed tomography (SPECT) with computed tomography coronary angiography (CTCA) for the detection of obstructive coronary artery disease (CAD) in patients with stable angina. 376 symptomatic patients (254 men, 122 women, mean age 60.4 ± 10.0 years) referred for noninvasive stress testing (exercise bicycle test and/or SPECT) and invasive coronary angiography were included. All patients underwent additional 64-slice CTCA. The diagnostic performance of exercise bicycle testing (ST segment depression), SPECT (reversible perfusion defect) and CTCA (≥50% lumen diameter reduction) was presented as sensitivity, specificity, positive and negative predictive value (PPV and NPV) to detect or rule out obstructive CAD with quantitative coronary angiography as reference standard. Comparisons of exercise bicycle testing versus CTCA (n = 334), and SPECT versus CTCA (n = 61) were performed. The diagnostic performance of exercise bicycle testing was significantly (P value < 0.001) lower compared to CTCA: sensitivity of 76% (95% CI, 71-82) vs. 100% (95% CI, 97-100); specificity of 47% (95% CI, 36-58) vs. 74% (95% CI, 63-82). We observed a PPV of 70% (95% CI, 65-75) vs. 91% (95% CI, 87-94); and NPV of 30% (95%, 25-35) vs. 99% (95%, 90-100). There was a statistically significant difference in sensitivity (P value < 0.05) between SPECT and CTCA: 89% (95% CI, 75-96) vs. 98% (95% CI, 87-100); but not in specificity (P value > 0.05): 77% (95% CI, 50-92) vs. 82% (95% CI, 56-95). We observed a PPV of 91% (95% CI, 77-97) vs. 93% (95% CI, 81-98); and NPV of 72% (95%, 46-89) vs. 93% (95%, 66-100). SPECT and CTCA yielded higher diagnostic performance compared to traditional exercise bicycle testing for the detection and rule out of obstructive CAD in patients with stable angina.Entities:
Mesh:
Year: 2011 PMID: 21222035 PMCID: PMC3326370 DOI: 10.1007/s10554-010-9785-y
Source DB: PubMed Journal: Int J Cardiovasc Imaging ISSN: 1569-5794 Impact factor: 2.357
Patient demographics (n = 376)
|
| 376 |
| Typical angina | 191 (50) |
| Atypical angina | 92 (25) |
| Nonanginal chest pain | 92 (25) |
| Men | 254 (68) |
| Age (years)a | 60.4 ± 10.0 |
| BMI (kg/m2)a | 27.3 ± 4.1 |
| Risk factors | |
| Hypertensionb | 170 (45) |
| Hypercholesterolemiac | 199 (53) |
| Diabetes mellitusd | 56 (15) |
| Smoker | 88 (23) |
| Family history of CADe | 64 (17) |
| Obesityf | 79 (21) |
Values are n (%) unless otherwise indicated
aMean and standard deviation
bBlood pressure 140/90 mm Hg or treatment for hypertension
cTotal cholesterol > 180 mg/dL or treatment for hypercholesterolemia
dTreatment with oral antidiabetic medication or insulin
eFamily history of coronary artery disease (CAD), having first- or second-degree relatives with premature CAD (age < 55 years)
fBody mass index (BMI) 30 kg/m2
Diagnostic performance and predictive value of exercise bicycle test, SPECT and CTCA for the detection of obstructive CAD (patient-based analysis)
| Prevalence, |
| TP | TN | FP | FN | Sensitivity | Specificity | PPV, | NPV, | +LR | −LR | c-index | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Exercise bicycle test (conclusive outcome) | 76 | 258 | 140 | 36 | 27 | 55 | 72 (65–78) | 57 (44–69) | 84 (77–89) | 40 (30–50) | 1.68 | 0.49 | 0.645 (0.564–0.725) |
| CTCA | 76 | 258 | 194 | 45 | 18 | 1 | 99 (97–100) | 71 (58–82) | 92 (87–95) | 98 (87–100) | 3.48 | 0.01 | 0.855 (0.786–0.923) |
Exercise bicycle test (conclusive outcome) and SPECT | 75 | 319 | 179 | 49 | 31 | 60 | 75 (69–80) | 61 (50–72) | 85 (80–90) | 45 (36–55) | 1.93 | 0.41 | 0.685 (0.615–0.754) |
| CTCA | 75 | 319 | 237 | 59 | 21 | 2 | 99 (97–100) | 74 (63–83) | 92 (88–95) | 97 (88–99) | 3.77 | 0.01 | 0.860 (0.800–0.920) |
Exercise bicycle test (conclusive and inconclusive) outcome) | 74 | 334 | 188 | 41 | 47 | 58 | 76 (71–82) | 47 (36–58) | 70 (65–75) | 30 (25–35) | 1.43 | 0.51 | 0.627 (0.557–0.698) |
| CTCA | 74 | 334 | 245 | 65 | 23 | 1 | 100 (97–100) | 74 (63–82) | 91 (87–94) | 99 (90–100) | 3.81 | 0.01 | 0.897 (0.846–0.947) |
| SPECT | 72 | 61 | 39 | 13 | 4 | 5 | 89 (75–96) | 77 (50–92) | 91 (77–97) | 72 (46–89) | 3.77 | 0.15 | 0.842 (0.718–0.967) |
| CTCA | 72 | 61 | 43 | 14 | 3 | 1 | 98 (87–100) | 82 (56–95) | 93 (81–98) | 93 (66–100) | 5.53 | 0.03 | 0.877 (0.758–0.996) |
+LR indicates positive likelihood ratio, −LR negative likelihood ratio, N number, TP true positives, TN true negatives, FP false positives, FN false negatives, NPV negative predictive value, PPV positive predictive value. Values in parentheses represent upper and lower bound for 95% confidence interval
Agreement analysis between CTCA and exercise bicycle test, and CTCA and SPECT (patient based analysis)
|
| Exercise bicycle test (conclusive outcome) | |||||
| TP | TN | FP | FN | |||
| CTCA | TP ( | 139 | 55 | |||
| TN ( | 30 | 15 | ||||
| FP ( | 6 | 12 | ||||
| FN ( | 1 | 0 | ||||
|
| Exercise bicycle test (conclusive outcome) and SPECT | |||||
| CTCA | TP | TN | FP | FN | ||
| TP ( | 177 | 60 | ||||
| TN ( | 42 | 17 | ||||
| FP ( | 7 | 14 | ||||
| FN ( | 2 | 0 | ||||
|
| SPECT | |||||
| TP | TN | FP | FN | |||
| CTCA | TP ( | 38 | 5 | |||
| TN ( | 12 | 2 | ||||
| FP ( | 1 | 2 | ||||
| FN ( | 1 | 0 | ||||
|
| Exercise bicycle test (conclusive and inconclusive outcome) | |||||
| TP | TN | FP | FN | |||
| CTCA | TP ( | 187 | 58 | |||
| TN ( | 35 | 30 | ||||
| FP ( | 6 | 17 | ||||
| FN ( | 1 | 0 | ||||
N indicates number, TP true positives, TN true negatives, FP false positives, FN false negatives, NPV negative predictive value, SPECT single photon emission computed tomography
CTCA protocol
| Patient preparation | 64-slice CTa | Dual-source CTb |
| Betablockers (dose, oral) | Yes | No |
| Lorazepam (dose, oral) | Yes | No |
| Nitroglycirine (0.4 mg/dose, sublingual) | No | Yes |
| Scan parameters | ||
| No. of tubes | 1 | 2 |
| No. of detectors | 32 × 2–64 | 32 × 2–64 |
| Collimation (mm) | 32 × 2 × 0.6 mmc | 32 × 2 × 0.6 mmc |
| Gantry rotation time (ms) | 330 | 330 |
| Effective temporal resolution (ms) | 165 msd | 83 msd |
| Pitch | 0.20 | 0.20–0.53 |
| kV | 120 | 120 |
| Full tube current (mA) | 800–900 | 625 |
| ECG pulsing | Yes | Yes |
| Scan time range (s) | 15–20 | 5–15 |
| Bolus tracking | Yes | Yes |
| Contrast volume (mL) | 50–120 | 60–100 |
| Contrast agent (mgl/mL) | 400 | 370 |
| Saline chaser volume (mL) | 40 | 40 |
| Injection rate (mL/sec) | 4.0–5.0 | 5.5 |
| Image reconstruction | ||
| Effective slice width (mm) | 0.75 | 0.75 |
| Reconstruction interval (mm) | 0.4 | 0.4 |
| Field of view (mm) | 180 | 180 |
| Convolution filter | Medium/sharp | Medium/sharp |
aSensation®, Siemens, Forchheim, Germany
bDefinition®, Siemens, Forchheim, Germany
cZ-sharp® Technology Siemens, Forchheim, Germany
dSingle-segmental reconstruction algorithm